S. Rosenbloom
Last active: 1/26/2016

Lessons learned from developing a drug evidence base to support pharmacovigilance.

Smith JC, Denny JC, Chen Q, Nian H, Spickard A, Rosenbloom ST, Miller RA
Appl Clin Inform. 2013 4 (4): 596-617

PMID: 24454585 · PMCID: PMC3885918 · DOI:10.4338/ACI-2013-08-RA-0062

OBJECTIVE - This work identified challenges associated with extraction and representation of medication-related information from publicly available electronic sources.

METHODS - We gained direct observational experience through creating and evaluating the Drug Evidence Base (DEB), a repository of drug indications and adverse effects (ADEs), and supplemented this through literature review. We extracted DEB content from the National Drug File Reference Terminology, from aggregated MEDLINE co-occurrence data, and from the National Library of Medicine's DailyMed. To understand better the similarities, differences and problems with the content of DEB and the SIDER Side Effect Resource, and Vanderbilt's MEDI Indication Resource, we carried out statistical evaluations and human expert reviews.

RESULTS - While DEB, SIDER, and MEDI often agreed on medication indications and side effects, cross-system shortcomings limit their current utility. The drug information resources we evaluated frequently employed multiple, disparate vaguely related UMLS concepts to represent a single specific clinical drug indication or adverse effect. Thus, evaluations comparing drug-indication and drug-ADE coverage for such resources will encounter substantial numbers of false negative and false positive matches. Furthermore, our review found that many indication and ADE relationships are too complex - logically and temporally - to represent within existing systems.

CONCLUSION - To enhance applicability and utility, future drug information systems deriving indications and ADEs from public resources must represent clinical concepts uniformly and as precisely as possible. Future systems must also better represent the inherent complexity of indications and ADEs.

MeSH Terms (9)

Adverse Drug Reaction Reporting Systems Drug Labeling Evidence-Based Medicine Humans MEDLINE Pharmacovigilance Reproducibility of Results United States United States Food and Drug Administration

Connections (2)

This publication is referenced by other Labnodes entities: